نتایج جستجو برای: 52 high week

تعداد نتایج: 2230247  

Journal: :Diabetes Care 2021

OBJECTIVE In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine 100 units/mL and glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control in type 2 diabetes uncontrolled with GLP-1 RAs over 26 weeks versus continuing prior RA. A prespecified, 26-week, single-arm extension aimed determine durability i...

Journal: :Archives of general psychiatry 1996
W Ling D R Wesson C Charuvastra C J Klett

BACKGROUND Buprenorphine is a partial agonist at the mu-opioid receptor that has been proposed as an alternative to traditional full agonist maintenance therapy for the treatment of opioid addiction. We report on a clinical trial in which the relative safety and efficacy of long-term fixed-dose buprenorphine maintenance was examined in comparison to low- and high-dose methadone maintenance. M...

Journal: :Atherosclerosis 2012
Makoto Kinoshita Yasuyuki Fujita Minako Katayama Rie Baba Maki Shibakawa Kimiko Yoshikawa Nobuyuki Katakami Yutaka Furukawa Tomio Tsukie Tohru Nagano Yasuo Kurimoto Kazuo Yamasaki Nobuhiro Handa Yukikatsu Okada Kaori Kuronaka Yukiko Nagata Yoshihiro Matsubara Masanori Fukushima Takayuki Asahara Atsuhiko Kawamoto

BACKGROUND Our phase I/IIa clinical trial revealed that intramuscular transplantation of autologous, GCSF-mobilized CD34+ cells was safe, feasible and potentially effective at week 4 and 12 post cellular therapy in 17 patients with chronic critical limb ischemia (CLI) (5 patients with atherosclerotic peripheral arterial disease (PAD) and 12 with Buerger's disease). However, long-term outcome of...

Journal: :Actas dermo-sifiliograficas 2017
D Morgado-Carrasco X Fustà-Novell J Riera Monroig J M Mascaró Galy

Please cite this article as: Morgado-Carrasco D, Fustà-Novell X, Riera Monroig J, Mascaró Galy JM. RF-The METOP Study: Further Evidence for the Use of Subcutaneous Methotrexate in Psoriasis. Actas Dermosifiliogr. 2017;108:865--866. ∗ Corresponding author. E-mail address: [email protected] (J.M. Mascaró Galy). patients, and side effects that required drug withdrawal in 6.9%. A clinica...

2012
Philip Tønnesen Hans Lauri Roland Perfekt Karl Mann Anil Batra

A nicotine mouth spray has advantages over other acute forms of nicotine replacement therapy, such as a faster uptake of nicotine and faster relief of craving. This multicentre, randomised (2:1), double-blind, placebo-controlled efficacy and safety study evaluated self-reported, carbon monoxide-verified continuous abstinence from smoking from week 2 until weeks 6, 24, and 52 in 479 smokers (≥ 1...

2009
J H Best K S Boye R R Rubin D Cao T H Kim M Peyrot

AIMS To assess treatment satisfaction and weight-related quality of life (QOL) in subjects with Type 2 diabetes treated with exenatide once weekly (QW) or twice daily (BID). METHODS In this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and/or oral glucose-lowering medications received either exenatide QW or BID during weeks 1-30; thereafter, s...

2017
Ernest H. Choy Corrado Bernasconi Maher Aassi Jose Fernando Molina Oscar Massimiliano Epis

OBJECTIVE To compare clinical effectiveness between tocilizumab and tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and inadequate response to conventional synthetic disease-modifying antirheumatic drugs initiating biologic therapy. METHODS Patients prescribed tocilizumab (intravenous) or TNFi were prospectively observed in routine clinical practice for 52 w...

2017
Nagamu Inoue Kiyonori Kobayashi Makoto Naganuma Fumihito Hirai Morio Ozawa Dilek Arikan Bidan Huang Anne M. Robinson Roopal B. Thakkar Toshifumi Hibi

BACKGROUND/AIMS Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks rolled over from the 52 week clinical trial (NCT01243671). METHODS Patients initiated adalimumab therapy at 160 mg at week 0, followed by 80 mg at week 2, foll...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید